[Update] AstraZeneca to buy a CAR-T expert?
[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca's CEO Pascal…
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to Report[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca's CEO Pascal…
Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer…
Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company…
Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich…
Just a week after announcing its intention to launch an IPO in the United States,…
A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an…
Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic…
Exactly one month ago, the article "Cellectis is preparing its IPO in the U.S" explained…
Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex…